MMEA
RXRX icon

Main Management ETF Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Main Management ETF Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-142,914
Closed -$723K – 184
2025
Q2 		$723K Buy
142,914
+2,328
+2% +$11.4K 0.03% 115
2025
Q1 		$744K Buy
+140,586
New +$1.02M 0.04% 96

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Main Management ETF Advisors's RXRX Position: Q3 2025 in Review

Main Management ETF Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 142,914 shares — an estimated $723K sold.

Main Management ETF Advisors first reported a position in RXRX in Q1 2025 and held it in 2 quarters. The position peaked at $744K in Q1 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Main Management ETF Advisors reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 142,914 Recursion Pharmaceuticals shares in Q3 2025, an estimated $723K.
  • Main Management ETF Advisors first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Main Management ETF Advisors's Recursion Pharmaceuticals position peaked at $744K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Main Management ETF Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.